2023
Sputum alarmins delineate distinct T2 cytokine pathways and unique subtypes of patients with asthma
Gautam S, Chu J, Cohen A, Kaur R, Lee S, Wilson G, Liu Q, Gomez J, Rajaveen H, Yan X, Cohn L, Clark B, Chupp G. Sputum alarmins delineate distinct T2 cytokine pathways and unique subtypes of patients with asthma. Allergy 2023, 78: 3274-3277. PMID: 37874609, PMCID: PMC10842366, DOI: 10.1111/all.15915.Peer-Reviewed Original ResearchDifferences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19
Liu Y, Rajeevan H, Simonov M, Lee S, Wilson F, Desir G, Vinetz J, Yan X, Wang Z, Clark B, Possick J, Price C, Lutchmansingh D, Ortega H, Zaeh S, Gomez J, Cohn L, Gautam S, Chupp G. Differences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3383-3390.e3. PMID: 37454926, PMCID: PMC10787810, DOI: 10.1016/j.jaip.2023.07.006.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseType 2 inflammationCOVID-19 severitySOFA scoreAirway diseaseNoneosinophilic asthmaSequential Organ Failure Assessment scoreOrgan Failure Assessment scoreSevere coronavirus disease 2019Higher SOFA scoreMedian SOFA scoreRetrospective cohort studyObstructive pulmonary diseaseOdds of mortalityLower SOFA scoresCells/μLCOVID-19 outcomesCoronavirus disease 2019Logistic regression analysisCOVID-19Clinical confoundersAsthma patientsCohort studyImmunological factorsClinical featuresIs there a best strategy to prevent asthma exacerbations in inner-city patients with asthma?
Zaeh S, Chupp G, Eakin M. Is there a best strategy to prevent asthma exacerbations in inner-city patients with asthma? Annals Of Allergy Asthma & Immunology 2023, 132: 11-12. PMID: 37433383, PMCID: PMC10774450, DOI: 10.1016/j.anai.2023.07.003.Commentaries, Editorials and LettersEfficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose C, Hellqvist Å, Roseti S, Molfino N, Llanos J, Martin N, Bowen K, Griffiths J, Parnes J, Colice G. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. American Journal Of Respiratory And Critical Care Medicine 2023, 208: 13-24. PMID: 37015033, PMCID: PMC10870853, DOI: 10.1164/rccm.202210-2005oc.Peer-Reviewed Original ResearchConceptsAsthma exacerbation rateUncontrolled asthmaExacerbation rateSecondary outcomesClinical trialsOverall populationRelevant subgroupsMeaningful reductionEfficacy of tezepelumabExacerbation-related hospitalizationsSafety of tezepelumabPlacebo-controlled trialEmergency department visitsInflammatory biomarker levelsNitric oxide levelsAdverse eventsAllergy statusBaseline bloodClinical characteristicsDepartment visitsPooled analysisNAVIGATOR trialBiomarker levelsOxide levelsTezepelumabEffect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study
Menzies-Gow A, Bourdin A, Chupp G, Israel E, Hellqvist Å, Hunter G, Roseti S, Ambrose C, Llanos J, Cook B, Corren J, Colice G. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study. Annals Of Allergy Asthma & Immunology 2023, 131: 343-348.e2. PMID: 37263380, DOI: 10.1016/j.anai.2023.05.028.Peer-Reviewed Original ResearchConceptsExacerbation-related hospitalizationsHealthcare utilizationUncontrolled asthmaNAVIGATOR studyAsthma-related healthcare utilizationEffect of tezepelumabPatient healthcare utilizationRecipients of placeboThymic stromal lymphopoietinHealth-related qualityIntensive care daysHuman monoclonal antibodySubcutaneous tezepelumabAsthma controlAsthma exacerbationsLung functionSpecialist visitsEmergency departmentCare daysOverall burdenTezepelumabMAIN OUTCOMEPlaceboAmbulance transportHospitalizationDupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status
Rabe K, Pavord I, Busse W, Chupp G, Izuhara K, Altincatal A, Gall R, Pandit‐Abid N, Deniz Y, Rowe P, Jacob‐Nara J, Radwan A. Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status. Allergy 2023, 78: 2148-2156. PMID: 37073882, DOI: 10.1111/all.15747.Peer-Reviewed Original ResearchConceptsParent study baselineType 2 inflammationPre-bronchodilator FEVAsthma exacerbation rateType 2 asthmaAllergic asthmaExacerbation rateSevere asthma exacerbation ratesSevere type 2 asthmaAsthma Control Questionnaire scoreACQ-5 scoresReduced exacerbation ratesLong-term outcomesLong-term treatmentAllergic statusDupilumab efficacyGINA guidelinesQUEST studyWeek 96Asthma controlUncontrolled asthmaWeek 48Allergic phenotypeLung functionQuestionnaire scoresRemission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers In Immunology 2023, 14: 1150162. PMID: 37122713, PMCID: PMC10131245, DOI: 10.3389/fimmu.2023.1150162.Peer-Reviewed Original ResearchConceptsSevere eosinophilic asthmaClinical remissionEosinophilic asthmaRemission definitionsClinical practiceAsthma Control Test scoresBetter ACT scoresProportion of patientsSubset of patientsACT scoreMepolizumab therapyMepolizumab treatmentOral corticosteroidsPrior exacerbationsOC useSevere asthmaBaseline characteristicsExpiratory volumeLung functionRemission outcomesMedical recordsDisease progressionTreatment outcomesRemissionTreatment goals
2022
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma
Corren J, Wechsler M, Chupp G, Roseti S, Hellqvist Å, Martin N, Llanos J, Ambrose C, Colice G. Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma. The Journal Of Allergy And Clinical Immunology In Practice 2022, 11: 943-945.e2. PMID: 36375743, DOI: 10.1016/j.jaip.2022.10.042.Peer-Reviewed Original Research
2020
Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure
Murphy K, Chipps B, Beuther D, Wise R, McCann W, Gilbert I, Eudicone J, Gandhi H, Harding G, Coyne K, Zeiger R, Board P, Kobernick A, Mohammad A, Cherry A, Fein A, Gaines A, Ramsey A, Michaud A, Palmer A, Kim A, Smith A, White A, Ricci A, Kettelhut B, Modena B, Stone B, Rolston B, Schnapf B, Krajicek B, Kraft C, Hopkins C, Natalie C, Anderson C, Czajkowski C, Arce D, Hamlin D, Hill D, Mares D, Pham D, Liao D, Simmons D, Johnson D, Jhaveri D, Maselli D, Kerwin E, Schuman E, Sher E, Bleecker E, Rakowski E, Hsu F, Averill F, Barsanti F, Gross G, Chupp G, Head G, Nasir H, Lee H, Barjaktarevic I, Cook J, Krainson J, Pearl J, Bellak J, Perez-Fernandez J, Rehm J, Trevor J, Most J, Hanson J, Blessing-Moore J, Biller J, Gedell J, Southard J, Chancellor J, Ilowite J, Romeo J, Mercado J, Fisher J, Greiwe J, Gregory K, Nadeau K, Shenoy K, Tan L, Stefanowicz L, Humes L, Bowers L, O’Connor M, Perez M, White M, Hegewald M, Wilson M, Sikora M, Morganroth M, Smith M, Farooqui N, Lesch N, Jain N, Parikh N, Hartog N, Luthin P, Stewart P, O’Connor P, Schochet P, Goldberg P, Patel P, Chinthrajah R, Sidhu R, Ayinla R, Brown R, Stadtler R, Wachs R, Balkissoon R, Duplantier R, Puente R, Settipane R, Mustafa S, Surani S, Jawad S, Adams S, Villegas S, Al-Farra S, Subramanian S, Bains S, Kelsen S, Wise S, Estrella-Eades S, Smith S, Qureshi T, Chen T, Kelbel T, Miller T, Jain V, Soong W, Soler X, Mattar Z. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2263-2274.e5. PMID: 32387166, DOI: 10.1016/j.jaip.2020.02.042.Peer-Reviewed Original ResearchConceptsAsthma controlAsthma Control Test scoresAsthma control toolPhysician-diagnosed asthmaCut pointsLogistic regression analysisAsthma impairmentExacerbation historyAsthma severityFuture exacerbationsTest-retest reliabilityRisk QuestionnaireSymptom impairmentAsthmaSpecialty practicePatientsRisk questionsGlobal InitiativeImpairmentAirQRisk increaseCharacteristic curveExacerbationRegression analysisComposite measure
2017
Multiparameter Single Cell Profiling of Airway Inflammatory Cells
Yao Y, Welp T, Liu Q, Niu N, Wang X, Britto CJ, Krishnaswamy S, Chupp G, Montgomery RR. Multiparameter Single Cell Profiling of Airway Inflammatory Cells. Cytometry Part B Clinical Cytometry 2017, 92: 12-20. PMID: 27807928, PMCID: PMC5250532, DOI: 10.1002/cyto.b.21491.Peer-Reviewed Original ResearchConceptsSingle-cell methodsComplex trait diseasesSubgroup of asthmaticsSingle-cell analysisMultiparameter single cell analysisMillions of patientsTranscriptional analysisImmunologic underpinningsInduced sputumAirway diseaseAsthmatic patientsAirway samplesCell subsetsImmune statusFunctional statusClinical severityDistinct biologic mechanismsTreatment successPhysiologic manifestationsBiologic mechanismsCystic fibrosisCellular analysisPatientsCytometry studiesU.S. population
2011
Pathways Activated during Human Asthma Exacerbation as Revealed by Gene Expression Patterns in Blood
Bjornsdottir US, Holgate ST, Reddy PS, Hill AA, McKee CM, Csimma CI, Weaver AA, Legault HM, Small CG, Ramsey RC, Ellis DK, Burke CM, Thompson PJ, Howarth PH, Wardlaw AJ, Bardin PG, Bernstein DI, Irving LB, Chupp GL, Bensch GW, Bensch GW, Stahlman JE, Karetzky M, Baker JW, Miller RL, Goodman BH, Raible DG, Goldman SJ, Miller DK, Ryan JL, Dorner AJ, Immermann FW, O'Toole M. Pathways Activated during Human Asthma Exacerbation as Revealed by Gene Expression Patterns in Blood. PLOS ONE 2011, 6: e21902. PMID: 21779351, PMCID: PMC3136489, DOI: 10.1371/journal.pone.0021902.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsAsthma exacerbationsBlood mononuclear cellsMononuclear cellsAnalysis of PBMCsAntigen-independent T-cell activationMajor unmet clinical needHuman asthma exacerbationsBronchoalveolar lavage samplesUnmet clinical needT cell activationStable asthmaExacerbation episodesGene expression signaturesRespiratory infectionsAirway tissueLavage samplesAdaptive immunityExacerbationAnalysis of covarianceCell activationInnate immunityLymphocyte activationLevel of expressionClinical needTargeting ST2L Potentiates CpG-Mediated Therapeutic Effects in a Chronic Fungal Asthma Model
Ramaprakash H, Shibata T, Duffy KE, Ismailoglu UB, Bredernitz RM, Moreira AP, Coelho AL, Das AM, Fursov N, Chupp GL, Hogaboam CM. Targeting ST2L Potentiates CpG-Mediated Therapeutic Effects in a Chronic Fungal Asthma Model. American Journal Of Pathology 2011, 179: 104-115. PMID: 21640974, PMCID: PMC3123853, DOI: 10.1016/j.ajpath.2011.03.032.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAspergillosis, Allergic BronchopulmonaryAspergillus fumigatusAsthmaBlotting, WesternBronchial HyperreactivityCase-Control StudiesChemokine CXCL9Chronic DiseaseDisease Models, AnimalEnzyme-Linked Immunosorbent AssayFemaleFibrosisHumansImmunoenzyme TechniquesImmunoglobulin GLungMiceMice, Inbred C57BLOligodeoxyribonucleotidesReceptors, Interleukin-1Reverse Transcriptase Polymerase Chain ReactionRNA, MessengerToll-Like Receptor 9ConceptsAsthmatic miceExperimental asthmaDendritic cellsTherapeutic effectDay 28Live A. fumigatus conidiaControl dendritic cellsMucus cell metaplasiaKey pathological featureCell-associated receptorsA. fumigatus conidiaProtein expression levelsAirway hyperresponsivenessCXCL9 levelsFungal asthmaPeribronchial fibrosisAsthma modelIL-12p70Time-dependent mannerAllergic inflammationAsthma severityCell metaplasiaIL-33Therapeutic blockadeC57BL/6 mice
2009
The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases
Ober C, Chupp GL. The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. Current Opinion In Allergy And Clinical Immunology 2009, 9: 401-408. PMID: 19644363, PMCID: PMC3018778, DOI: 10.1097/aci.0b013e3283306533.Peer-Reviewed Original ResearchConceptsChitinase-like proteinsNovel asthma susceptibility genesAsthma susceptibility genesRegulatory SNPsNonsynonymous SNPsNonfunctional allelesDiverse ancestryGenetic studiesChitinase activityGenesSusceptibility genesFunctional studiesChitinaseDuplication alleleMammalian chitinaseProteinMajor chitinaseEnzyme activityPolymorphismSNPsChiaAllelesCHIT1CHI3L1Present review
2008
Effect of Variation in CHI3L1 on Serum YKL-40 Level, Risk of Asthma, and Lung Function
Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, Radford S, Parry RR, Heinzmann A, Deichmann KA, Lester LA, Gern JE, Lemanske RF, Nicolae DL, Elias JA, Chupp GL. Effect of Variation in CHI3L1 on Serum YKL-40 Level, Risk of Asthma, and Lung Function. New England Journal Of Medicine 2008, 358: 1682-1691. PMID: 18403759, PMCID: PMC2629486, DOI: 10.1056/nejmoa0708801.Peer-Reviewed Original ResearchMeSH KeywordsAdipokinesAdolescentAdultAgedAged, 80 and overAsthmaBiomarkersBronchial HyperreactivityCase-Control StudiesChildChitinase-3-Like Protein 1FemaleFounder EffectGenetic Predisposition to DiseaseGenotypeGlycoproteinsHumansLectinsMaleMiddle AgedPhenotypePolymorphism, Single NucleotidePulmonary VentilationConceptsSerum YKL-40 levelsYKL-40 levelsLung functionYears of ageBronchial hyperresponsivenessPulmonary functionSingle nucleotide polymorphismsYKL-40Elevated serum YKL-40 levelsBirth cohortChitinase-like protein YKL-40Presence of asthmaProtein YKL-40Risk of asthmaPromoter single nucleotide polymorphismsEuropean descentSubepithelial basement membraneCase-control populationCase patientsAsthma statusAsthmaHigh riskChitinase 3Same single nucleotide polymorphismCHI3L1
2007
A Chitinase-like Protein in the Lung and Circulation of Patients with Severe Asthma
Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J, Coyle AJ, Kiener P, Cullen M, Grandsaigne M, Dombret MC, Aubier M, Pretolani M, Elias JA. A Chitinase-like Protein in the Lung and Circulation of Patients with Severe Asthma. New England Journal Of Medicine 2007, 357: 2016-2027. PMID: 18003958, DOI: 10.1056/nejmoa073600.Peer-Reviewed Original ResearchConceptsSerum YKL-40 levelsYKL-40 levelsSeverity of asthmaYKL-40Chitinase-like proteinsParis cohortOral corticosteroid useCohort of patientsRescue inhaler useSubgroup of patientsCirculation of patientsCorticosteroid useSevere asthmaAirway remodelingClinical characteristicsExpiratory volumeAcidic mammalian chitinasePatient populationHigh serumAsthmaImmunohistochemical analysisPatientsAnimal modelsLocus of expressionMorphometric quantitation
2005
Yoga intervention for adults with mild-to-moderate asthma: a pilot study
Sabina AB, Williams A, Wall HK, Bansal S, Chupp G, Katz DL. Yoga intervention for adults with mild-to-moderate asthma: a pilot study. Annals Of Allergy Asthma & Immunology 2005, 94: 543-548. PMID: 15945557, DOI: 10.1016/s1081-1206(10)61131-3.Peer-Reviewed Original ResearchConceptsModerate asthmaYoga interventionOutcome measuresMasked clinical trialRescue inhaler useHealth care utilizationMini Asthma QualityQuality of lifeFinal followUsual careAsthma QualityExpiratory volumeInhaler useSymptom diaryTreat analysisCare utilizationSymptom scoresAsthma managementClinical indicesLife QuestionnaireClinical trialsIyengar yogaAsthmaControl groupPilot study
2004
Asthma: Mechanisms of Disease Persistence and Progression
Cohn L, Elias JA, Chupp GL. Asthma: Mechanisms of Disease Persistence and Progression. Annual Review Of Immunology 2004, 22: 789-815. PMID: 15032597, DOI: 10.1146/annurev.immunol.22.012703.104716.BooksConceptsIL-13Key effector cytokineAnti-inflammatory therapyIL-13 productionProduction of chemokinesProgression of diseaseAirway fibrosisAllergic asthmaAirway remodelingEffector cytokinesEosinophilic inflammationPersistent diseaseTh2 cytokinesEpithelial damageDisease progressionInflammatory responseTh2 cellsMucus productionSmooth muscleBronchial airwaysMatrix metalloproteinasesAnimal dataAsthmaDisease persistenceInflammation
1999
Airway remodeling in asthma
Elias J, Zhu Z, Chupp G, Homer R. Airway remodeling in asthma. Journal Of Clinical Investigation 1999, 104: 1001-1006. PMID: 10525034, PMCID: PMC408860, DOI: 10.1172/jci8124.Peer-Reviewed Original Research